Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4162 Functioning neuroendocrine neoplasms: Symptomatic control with 177Lu-DOTATATE

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is recommended in unresectable and metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs), however, recommendations for functioning NENs (F-NENs) are not well established. Besides PRRT impact in OS and PFS, real-life benefit in clinical control is also a relevant outcome, especially in F-NENs.

Conference:

Presenting Author: Santos A

Authors: Lopes-Pinto M, Silva D, Ribeiro S, Oliveira J, Ferreira G,

Keywords: neuroendocrine neoplasm, functioning neuroendocrine neoplasm, carcinoid syndrome, PRRT,

#3557 Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,

#3272 Carcinoid heart disease in Chilean NET patients with malignant carcinoid syndrome: Long-term cohort from a developing country

Introduction: Carcinoid heart disease (CHD) is an important cause of morbidity in patients with Neuroendocrine Tumors (NET) and could be associated with poorer prognosis. There is scarce data about CHD in low and middle-income countries, and its impact has not been studied in Latin American patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Carrillo D

Authors: Carrillo D, Muñoz-Medel M, Pinto M, Retamal I, Bravo L,

Keywords: carcinoid heart disease, carcinoid syndrome, prognostic factors, Latin America,

#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile

Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carrillo D

Authors: Carrillo D, Munoz-Anguita G, Madison A, Retamal I, Pinto M,

Keywords: Neuroendocrine, Carcinoid, Health-related quality of life.,

#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Munoz Medel M

Authors: Munoz-Medel M, Cordova Delgado M, Pinto M, Bravo M, Retamal I,

Keywords: Neuroendocrine, Chromogranin A, Biomarker,